{"id":469178,"date":"2021-03-31T17:03:33","date_gmt":"2021-03-31T21:03:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469178"},"modified":"2021-03-31T17:03:33","modified_gmt":"2021-03-31T21:03:33","slug":"edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/","title":{"rendered":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MENLO PARK, Calif.<\/span>, March 31, 2021<\/span> \/PRNewswire\/ —\u00a0Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop and commercialize new therapies targeting the fight against cancer, today announced that it has transferred certain worldwide rights to novel DNA-damage response (DDR) inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc. (“Rakovina”, TSX-V: RKV). <\/p>\n

\n

\n
\n \"(PRNewsfoto\/Edison
\n <\/a>\n <\/p>\n<\/p><\/div>\n

In exchange for transferring these rights, Edison Oncology has been issued common shares representing approximately 43% of the outstanding shares of Rakovina.\u00a0 Edison Oncology’s ownership in Rakovina is held by NewGen Therapeutics, Inc. a wholly-owned subsidiary of Edison Oncology.<\/p>\n

“We are pleased to work with the Rakovina Therapeutics team to establish this new company that will seek to develop new\u00a0cancer treatments based on novel DNA-damage response technologies”, said Mr. Jeffrey Bacha<\/span>, Edison Oncology’s chief executive officer.\u00a0 “Edison Oncology and its shareholders will benefit by virtue of our substantial ownership, which will provide opportunities for significant value creation as Rakovina advances its pipeline toward human clinical trials.”<\/p>\n

As a result of this transaction, Dennis Brown<\/span>, Ph.D., Edison Oncology’s chairman and Jeffrey Bacha<\/span>, Edison Oncology’s chief executive officer have been appointed to Rakovina’s Board of Directors. \u00a0Mr. Bacha has been appointed Rakovina’s executive chairman. <\/p>\n

Rakovina was capitalized through a private placement financing and will conduct lead optimization research under a collaboration agreement with the University of British Columbia.\u00a0 Rakovina’s common shares are expected to begin trading as a Tier 2 Issuer on the TSX Venture Exchange under the symbol “RKV” on or about Thursday, April 1, 2021<\/span>.<\/p>\n

\n About Edison Oncology Holding Corp.<\/b>\n <\/p>\n

Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer. Edison Oncology leverages a deep understanding of cancer biology and cancer pharmacology in order to identify and advance underdeveloped drug candidates with the potential to overcome treatment resistance and improve survival outcomes and quality of life for cancer patients. \u00a0Further information can be found at www.edisononcology.com<\/a>. <\/p>\n

\n About Rakovina Therapeutics Inc.<\/b>\n <\/p>\n

Rakovina Therapeutics’ focus is the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies.\u00a0 Further information can be found at www.rakovinatherapeutics.com<\/a>. <\/p>\n

\n Safe Harbor Statement<\/b>\n <\/p>\n

\n Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and research programs. \u00a0Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.\u00a0 The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company’s operations and clinical trials; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.\u00a0 <\/i>\n <\/p>\n

\n Investor Contact:<\/b>\n <\/p>\n

Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com<\/a><\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics-301260035.html<\/a><\/p>\n

SOURCE Edison Oncology Holding Corp.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MENLO PARK, Calif., March 31, 2021 \/PRNewswire\/ —\u00a0Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop and commercialize new therapies targeting the fight against cancer, today announced that it has transferred certain worldwide rights to novel DNA-damage response (DDR) inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc. (“Rakovina”, TSX-V: RKV). In exchange for transferring these rights, Edison Oncology has been issued common shares representing approximately 43% of the outstanding shares of Rakovina.\u00a0 Edison Oncology’s ownership in Rakovina is held by NewGen Therapeutics, Inc. a wholly-owned subsidiary of Edison Oncology. “We are pleased to work with the Rakovina Therapeutics team to establish this new company that will seek to develop new\u00a0cancer treatments … <\/p>\n

Continue reading “Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469178","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEdison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MENLO PARK, Calif., March 31, 2021 \/PRNewswire\/ —\u00a0Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop and commercialize new therapies targeting the fight against cancer, today announced that it has transferred certain worldwide rights to novel DNA-damage response (DDR) inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc. (“Rakovina”, TSX-V: RKV). In exchange for transferring these rights, Edison Oncology has been issued common shares representing approximately 43% of the outstanding shares of Rakovina.\u00a0 Edison Oncology’s ownership in Rakovina is held by NewGen Therapeutics, Inc. a wholly-owned subsidiary of Edison Oncology. “We are pleased to work with the Rakovina Therapeutics team to establish this new company that will seek to develop new\u00a0cancer treatments … Continue reading "Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-31T21:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics\",\"datePublished\":\"2021-03-31T21:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/\"},\"wordCount\":609,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1439956\\\/Edison_Oncology_Holding_Corp_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/\",\"name\":\"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1439956\\\/Edison_Oncology_Holding_Corp_Logo.jpg\",\"datePublished\":\"2021-03-31T21:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1439956\\\/Edison_Oncology_Holding_Corp_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1439956\\\/Edison_Oncology_Holding_Corp_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk","og_description":"PR Newswire MENLO PARK, Calif., March 31, 2021 \/PRNewswire\/ —\u00a0Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop and commercialize new therapies targeting the fight against cancer, today announced that it has transferred certain worldwide rights to novel DNA-damage response (DDR) inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc. (“Rakovina”, TSX-V: RKV). In exchange for transferring these rights, Edison Oncology has been issued common shares representing approximately 43% of the outstanding shares of Rakovina.\u00a0 Edison Oncology’s ownership in Rakovina is held by NewGen Therapeutics, Inc. a wholly-owned subsidiary of Edison Oncology. “We are pleased to work with the Rakovina Therapeutics team to establish this new company that will seek to develop new\u00a0cancer treatments … Continue reading \"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-31T21:03:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics","datePublished":"2021-03-31T21:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/"},"wordCount":609,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/","name":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg","datePublished":"2021-03-31T21:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1439956\/Edison_Oncology_Holding_Corp_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edison-oncology-partners-dna-damage-response-inhibitor-program-with-rakovina-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469178"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469178\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}